Galectin Therapeutics Inc. (GALT) Jumps 8.02% on January 05

Equities Staff |

Galectin Therapeutics Inc. (GALT) was among the biggest gainers on the Russell 2000 for Tuesday January 05 as the stock popped 8.02% to $1.75, representing a gain of $0.13 per share. Some 219,491 shares traded hands on 675 trades, compared with an average daily volume of 127,840 shares out of a total float of 23.93 million. The stock opened at $1.62 and traded with an intraday range of $1.82 to $1.62.

After today's gains, Galectin Therapeutics Inc. reached a market cap of $41.88 million. Galectin Therapeutics Inc. has had a trading range between $4.50 and $1.50 over the last year, and it had a 50-day SMA of $2.18 and a 200-day SMA of $2.59.

Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.

Galectin Therapeutics Inc. is based out of Norcross, GA and has some 7 employees. Its CEO is Peter G. Traber.

For a complete fundamental analysis analysis of Galectin Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for GALT. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

IGEN Networks Corp.

iGen Networks Corp is engaged in investing in and managing for growth private high-tech companies that offer products and services in the domains of wireless broadband, software as a service,…

Private Markets

Uber

Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.